Osteoporosis and Osteopathy Markers in Patients with Mastocytosis

YAVUZ, AKIF SELIM; DOĞAN, Öner; BAYKAL, Can; SİNDEL, Dilşad; BÜYÜKBABANI, NESIMI; TANAKOL, Refik; ERER, Burak; ALPAY KANITEZ, NİLÜFER

Osteoporosis and Osteopathy Markers in Patients with Mastocytosis

Nilüfer Alpay KANITEZ, (İstanbul Üniversitesi, İstanbul Tıp Fakültesi, İstanbul, Türkiye)

Burak ERER, (İstanbul Üniversitesi, İstanbul Tıp Fakültesi, İstanbul, Türkiye)

Öner DOĞAN, (İstanbul Üniversitesi, İstanbul Tıp Fakültesi, İstanbul, Türkiye)

Nesimi BÜYÜKBABANİ, (İstanbul Üniversitesi, İstanbul Tıp Fakültesi, İstanbul, Türkiye)

Can BAYKAL, (İstanbul Üniversitesi, İstanbul Tıp Fakültesi, İstanbul, Türkiye)

Dilşad SİNDEL, (İstanbul Üniversitesi, İstanbul Tıp Fakültesi, İstanbul, Türkiye)

Refik TANAKOL, (İstanbul Üniversitesi, İstanbul Tıp Fakültesi, İstanbul, Türkiye)

Akif Selim YAVUZ (İstanbul Üniversitesi, İstanbul Tıp Fakültesi, İstanbul, Türkiye)

Turkish Journal of Hematology

0 1

Yıl: 2015 Cilt: 32 Sayı: 1 Sayfa Aralığı: 43 - 50 Metin Dili: Türkçe İndeks Tarihi: 29-07-2022

Osteoporosis and Osteopathy Markers in Patients with Mastocytosis

Öz:

Amaç: Sistemik mastositozlu (SM) hastalarda osteoporoz, osteoskleroz ve litik kemik lezyonları görülebilir. Bu çalışmada nadir bir hastalık olan SMde, kemik yoğunluk ölçümü (BMD), serumda kemik turnover belirteçleri ve triptaz düzeyi araştırılmıştır. Gereç ve Yöntemler: Çalışmaya 5i kadın, 12si erkek olmak üzere median yaşları 33 (20-64) olan toplam 17 hasta dahil edilmiştir. Hastaların BMDleri lomber vertebra (L1-L4), femur boynu ve distal radiustan dual enerji x-ray absorbitesi (DXA) yöntemi, kalkaneustan ise kantitatif ultrasonografi (USG) yöntemi kullanılarak ayrı ayrı hesaplanmıştır. Serum triptaz düzeyleri ile biyokimyasal kemik turnover belirteçlerileri arasındaki ilişki araştırılmıştır. Bulgular: Hastaların 12 tanesinde osteopeni (incelenen kemik alanlarının en az birinde T skoru <-1), 3 tanesinde ise osteoporoz (T skoru <-2,5) saptanmıştır. Kemik lezyonlarının şiddeti ile DXA sonuçları arasında korelasyon gösterilememiştir. Triptaz ve pridinolin seviyeleri ile hastalık şiddeti arasında pozitif korelasyon bulunmuştur (p<0,01). Sonuç: Osteosklerotik kemik lezyonları sebebiyle SMli hastalarda kemik tutulumu değerlendirmesi için DXA ve kalkaneus USG uygun teknikler değildir. Osteoklastik aktivite belirteçleri olan pridinolin, şiddetli hastalık aktivitesi ve kemik sklerozlarını değerlendirmede faydalıdır. Anahtar Sözcükler:

Anahtar Kelime:

Konular: Hematoloji

Sistemik Mastositozda Osteoporoz ve Osteopati Belirteçleri

Öz:

Objective: Osteoporosis, osteosclerosis, and lytic bone lesions have been observed in patients with systemic mastocytosis (SM). We examined bone mineral density (BMD) biochemical turnover markers and serum tryptase levels in SM, which is considered a rare disease. Materials and Methods: Seventeen adult patients (5 females, 12 males; median age: 33 years, range: 20-64) with mastocytosis were included in this study. We investigated the value of quantitative ultrasound (QUS) of the calcaneus in the assessment of BMD in SM patients, as well as BMD of the lumbar spine (L1-L4), femoral neck, and distal radius using dual energy x-ray absorptiometry (DXA) and plasma tryptase levels, biochemical markers of bone turnover. Results: At lumbar spine L1-L4, the femoral neck, and the distal radius or as calcaneus stiffness, 12 of 17 patients had T-scores of less than -1 at least at 1 site, reflecting osteopenia. Three of 17 patients had T-scores showing osteoporosis (T-score <-2.5). There was no relationship between DXA and bone lesion severity. We also found a significant positive correlation between tryptase levels and disease severity, as well as between disease severity and pyridinoline (p<0.01 by Spearman s test). Conclusion: DXA and calcaneal QUS may not be appropriate techniques to assess bone involvement in SM patients because of the effects of osteosclerosis. This study further shows that the osteoclastic marker pyridinoline is helpful in patients with severe disease activity and sclerotic bone lesions to show bone demineralization.

Anahtar Kelime:

Konular: Hematoloji

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Valent P, Akin C, Sperr WR, Mayerhofer M, Födinger M, Fritsche-Polanz R, Sotlar K, Escribano L, Arock M, Horny HP, Metcalfe DD. Mastocytosis: pathology, genetics, and current options for therapy. Leuk Lymphoma 2005;46:35-48.
2. Horny HP, Metcalfe DD, Bennett JM, Bain BJ, Akin C, Escribano L, Valent P. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW (eds). World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissue. 4th ed. Lyon, France, IARC, 2008.
3. Valent P, Horny HP, Escribano L, Longley BJ, Li CY, Schwartz LB, Marone G, Nuñez R, Akin C, Sotlar K, Sperr WR, Wolff K, Brunning RD, Parwaresch RM, Austen KF, Lennert K, Metcalfe DD, Vardiman JW, Bennett JM. Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk Res 2001;25:603-625.
4. Johansson C, Roupe G, Lindstedt G, Mellström D. Bone density, bone markers and bone radiological features in mastocytosis. Age Ageing 1996;25:1-7.
5. Kushnir-Sukhov NM, Brittain E, Reynolds JC, Akin C, Metcalfe DD. Elevated tryptase levels are associated with greater bone density in a cohort of patients with mastocytosis. Int Arch Allergy Immunol 2006;139:265-270.
6. Valent P, Akin C, Sperr WR, Escribano L, Arock M, Horny HP, Bennett JM, Metcalfe DD. Aggressive systemic mastocytosis and related mast cell disorders: current treatment options and proposed response criteria. Leuk Res 2003;27:635-641.
7. Chiappetta N, Gruber B. The role of mast cells in osteoporosis. Semin Arthritis Rheum 2006;36:32-36.
8. Fallon MD, Whyte MP, Teitelbaum SL. Systemic mastocytosis associated with generalized osteopenia. Histopathological characterization of the skeletal lesion using undecalcified bone from two patients. Hum Pathol 1981;12:813-820.
9. Brumsen C, Papapoulos SE, Lentjes EG, Kluin PM, Hamdy NA. A potential role for the mast cell in the pathogenesis of idiopathic osteoporosis in men. Bone 2002;31:556-561.
10. Weide R, Ehlenz K, Lorenz W, Walthers E, Klausmann M, Pflüger KH. Successful treatment of osteoporosis in systemic mastocytosis with interferon alpha-2b. Ann Hematol 1996;72:41-43.
11. Lehmann T, Beyeler C, Lämmle B, Hunziker T, Vock P, Olah AJ, Dahinden C, Gerber NJ. Severe osteoporosis due to systemic mast cell disease: successful treatment with interferon alpha- 2B. Br J Rheumatol 1996;35:898-900.
12. Lewiecki EM, Borges JL. Bone density testing in clinical practice. Arq Bras Endocrinol Metabol 2006;50:586-595.
13. Nazarian A, Cory E, Müller R, Snyder BD. Shortcomings of DXA to assess changes in bone tissue density and microstructure induced by metabolic bone diseases in rat models. Osteoporos Int 2009;20:123-132.
14. Khaw KT, Reeve J, Luben R, Bingham S, Welch A, Wareham N, Oakes S, Day N. Prediction of total and hip fracture risk in men and women by quantitative ultrasound of the calcaneus: EPIC- Norfolk prospective population study. Lancet 2004;363:197- 202.
15. Prins SH, Jørgensen HL, Jørgensen LV, Hassager C. The role of quantitative ultrasound in the assessment of bone: a review. Clin Physiol 1998;18:3-17.
16. Danese RD, Licata AA. Ultrasound of the skeleton: review of its clinical applications and pitfalls. Curr Rheumatol Rep 2001;3:245-248.
17. Nayak S, Olkin I, Liu H, Grabe M, Gould MK, Allen IE, Owens DK, Bravata DM. Meta-analysis: accuracy of quantitative ultrasound for identifying patients with osteoporosis. Ann Intern Med 2006;144:832-841.
18. Pusl T, Kenngott S, Bartl R, Baur A, Ludolph-Hauser D, Juengst D. A case of systemic mastocytosis associated with severe osteoporosis and pathologic fractures. Eur J Intern Med 2004;15:537-539.
19. Inaoui R, Petit B, Jaccard A, Bertin P, Trèves R. Aggressive systemic mastocytosis. Joint Bone Spine 2003;70:64-66.
20. Van de Ven AC, Erdtsieck RJ. Changes of bone mineral density, quantitative ultrasound parameters and markers of bone turnover during treatment of hyperthyroidism. Neth J Med 2008;66:428-432.
21. Schwartz LB, Sakai K, Bradford TR, Ren S, Zweiman B, Worobec AS, Metcalfe DD. The alpha form of human tryptase is the predominant type present in blood at baseline in normal subjects and is elevated in those with systemic mastocytosis. J Clin Invest 1995;96:2702-2710.
22. Akin C, Metcalfe DD. Surrogate markers of disease in mastocytosis. Int Arch Allergy Immunol 2002;127:133-136.
23. Sperr WR, Jordan JH, Fiegl M, Escribano L, Bellas C, Dirnhofer S, Semper H, Simonitsch-Klupp I, Horny HP, Valent P. Serum tryptase levels in patients with mastocytosis: correlation with mast cell burden and implication for defining the category of disease. Int Arch Allergy Immunol 2002;128:136-141.
24. Iddamalgoda A, Le QT, Ito K, Tanaka K, Kojima H, Kido H. Mast cell tryptase and photoaging: possible involvement in the degradation of extra cellular matrix and basement membrane proteins. Arch Dermatol Res 2008;300:69-76.

APA	ALPAY KANITEZ N, ERER B, DOĞAN Ö, BÜYÜKBABANI N, BAYKAL C, SİNDEL D, TANAKOL R, YAVUZ A (2015). Osteoporosis and Osteopathy Markers in Patients with Mastocytosis. , 43 - 50.
Chicago	ALPAY KANITEZ NİLÜFER,ERER Burak,DOĞAN Öner,BÜYÜKBABANI NESIMI,BAYKAL Can,SİNDEL Dilşad,TANAKOL Refik,YAVUZ AKIF SELIM Osteoporosis and Osteopathy Markers in Patients with Mastocytosis. (2015): 43 - 50.
MLA	ALPAY KANITEZ NİLÜFER,ERER Burak,DOĞAN Öner,BÜYÜKBABANI NESIMI,BAYKAL Can,SİNDEL Dilşad,TANAKOL Refik,YAVUZ AKIF SELIM Osteoporosis and Osteopathy Markers in Patients with Mastocytosis. , 2015, ss.43 - 50.
AMA	ALPAY KANITEZ N,ERER B,DOĞAN Ö,BÜYÜKBABANI N,BAYKAL C,SİNDEL D,TANAKOL R,YAVUZ A Osteoporosis and Osteopathy Markers in Patients with Mastocytosis. . 2015; 43 - 50.
Vancouver	ALPAY KANITEZ N,ERER B,DOĞAN Ö,BÜYÜKBABANI N,BAYKAL C,SİNDEL D,TANAKOL R,YAVUZ A Osteoporosis and Osteopathy Markers in Patients with Mastocytosis. . 2015; 43 - 50.
IEEE	ALPAY KANITEZ N,ERER B,DOĞAN Ö,BÜYÜKBABANI N,BAYKAL C,SİNDEL D,TANAKOL R,YAVUZ A "Osteoporosis and Osteopathy Markers in Patients with Mastocytosis." , ss.43 - 50, 2015.
ISNAD	ALPAY KANITEZ, NİLÜFER vd. "Osteoporosis and Osteopathy Markers in Patients with Mastocytosis". (2015), 43-50.

APA	ALPAY KANITEZ N, ERER B, DOĞAN Ö, BÜYÜKBABANI N, BAYKAL C, SİNDEL D, TANAKOL R, YAVUZ A (2015). Osteoporosis and Osteopathy Markers in Patients with Mastocytosis. Turkish Journal of Hematology, 32(1), 43 - 50.
Chicago	ALPAY KANITEZ NİLÜFER,ERER Burak,DOĞAN Öner,BÜYÜKBABANI NESIMI,BAYKAL Can,SİNDEL Dilşad,TANAKOL Refik,YAVUZ AKIF SELIM Osteoporosis and Osteopathy Markers in Patients with Mastocytosis. Turkish Journal of Hematology 32, no.1 (2015): 43 - 50.
MLA	ALPAY KANITEZ NİLÜFER,ERER Burak,DOĞAN Öner,BÜYÜKBABANI NESIMI,BAYKAL Can,SİNDEL Dilşad,TANAKOL Refik,YAVUZ AKIF SELIM Osteoporosis and Osteopathy Markers in Patients with Mastocytosis. Turkish Journal of Hematology, vol.32, no.1, 2015, ss.43 - 50.
AMA	ALPAY KANITEZ N,ERER B,DOĞAN Ö,BÜYÜKBABANI N,BAYKAL C,SİNDEL D,TANAKOL R,YAVUZ A Osteoporosis and Osteopathy Markers in Patients with Mastocytosis. Turkish Journal of Hematology. 2015; 32(1): 43 - 50.
Vancouver	ALPAY KANITEZ N,ERER B,DOĞAN Ö,BÜYÜKBABANI N,BAYKAL C,SİNDEL D,TANAKOL R,YAVUZ A Osteoporosis and Osteopathy Markers in Patients with Mastocytosis. Turkish Journal of Hematology. 2015; 32(1): 43 - 50.
IEEE	ALPAY KANITEZ N,ERER B,DOĞAN Ö,BÜYÜKBABANI N,BAYKAL C,SİNDEL D,TANAKOL R,YAVUZ A "Osteoporosis and Osteopathy Markers in Patients with Mastocytosis." Turkish Journal of Hematology, 32, ss.43 - 50, 2015.
ISNAD	ALPAY KANITEZ, NİLÜFER vd. "Osteoporosis and Osteopathy Markers in Patients with Mastocytosis". Turkish Journal of Hematology 32/1 (2015), 43-50.